Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes...nice! I communicated with the CEO earlier this year. She is ambitious, reliable, developed a great business model, follows up, even knows the fundamentals about the stock trading.
Looks that way. Hopefully some news on horizon
Awesome. Thank you
that were just 100 shares...for a week now 99% of the shares are traded in the upper 4 cents! That should set the baseline :)
No bid support so someone painted it down
Why down so much today?
Fantastic informative sticky. Thanks. Also, share numbers still unchanged (as predicted earlier this month)
A single small retailer tries to do s.th. here LOL....totally under the radar BUT WHAT A POTENTIAL! Tiny preserved SS on top of that
Yep she’s getting it lined up here
MSRM: with recent developments and sector an unbelievable opportunity
6M tradable shares only! 2 year pps high of $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
Mushrooms, Inc. (OTC: MSRM) Announces Diverse Business Development Team Assembled to Drive Company Growth.
ESTERO, Fla., Aug. 23, 2023 Mushrooms Inc. (OTC:MSRM) - Mushrooms Inc., proudly introduces its newly-formed Business Development Team, strategically assembled to harness the momentum generated by the company's new technology and Innovation lab development. Comprising accomplished professionals with diverse backgrounds, this team is poised to catapult Mushrooms Inc. into a new era of innovation and growth.
Dr. Reid Jilek's inclusion reflects Mushrooms Inc.'s commitment to synergizing academic prowess with industry innovation. Holding advanced degrees in medical, life sciences, and engineering, Dr. Jilek has published extensively in national and international scientific journals. He was both a Presidential Fellow and a White House Fellow Candidate. Dr. Jilek has developed in excess of 10,000 professional contacts worldwide in the healthcare industry and investment world. His leadership roles in private and public companies, combined with a network spanning the healthcare industry, establish him as a bridge between academia and business growth.
Alicia M. Fantozzi brings over two decades of international corporate and structured finance experience to the team. With a focused track record of driving growth and fostering strategic alliances, her appointment resonates with Mushrooms Inc.'s vision. Having held key roles in strategic initiatives, Alicia's extensive experience uniquely equips her to lead the team's efforts in expanding market presence and revenue streams.
Her role as Principal at ReGen establishes a seed-stage idea lab for biomimicry-based regenerative technologies for water and agriculture., with a concentrated focus on arranging financing, field trials and propagation of advanced innovation initiatives and evaluating complimentary environmental technologies for international sustainability initiatives, Food, Water & Natural Resource Security. Her background, strategic acumen, and commitment to sustainable business practices resonate with Mushrooms Inc.’s mission of revolutionizing the mushroom industry.
Dr. Hyder Khoja, is a leading figure in the life sciences field with over 22 years of expertise spanning drug discovery, developmental science, and policy innovation. Holding a Ph.D. in "Molecular Biology" from INP-ENSAT and post-doctoral training at Michigan State University, his education grounds his visionary approach. Dr. Khoja is a distinguished scientist and visionary in the psychedelic sector, who brings a profound focus to the team. Notably, he is personally committed to pioneering the resurrection of coma patients using psilocybin, adding a transformative dimension to Mushrooms Inc.'s initiatives in the psychedelic space. Dr. Khoja is senior lead scientist in the Company’s patent pending Mycelium thread project showcasing the vast background that he brings in support of diverse projects.
David Flores, CEO of PSYC Corporation which owns and operates Psychedelic Spotlight, an industry-leading media authority for the psychedelic sector, brings his visionary leadership to the team. His strategic thinking and experience in the psychedelic landscape perfectly aligns with Mushrooms Inc.'s aspirations for developing multiple facets of the Mushroom sector. His marketing expertise and industry knowledge is integral to the Company as it evolves.
"This enhanced Business Development Team represents a pivotal milestone for Mushrooms Inc.," said Donald Steinberg, Board Director of Mushrooms Inc. "As we make strides in the mushroom sector, our team's collective experience and expertise provide a robust foundation for innovation and growth."
"We are delighted to introduce our exceptional Business Development Team," said Kimberly Zawi Carlson, CEO of Mushrooms Inc. "I've had the privilege of collaborating with these amazing individuals over the past months and I feel that they will collectively bring to Mushrooms Inc what is needed to step forward. I'm honored to announce a formal collaboration with these remarkable and versatile professionals. This strategic step is a direct response to the increasing interest surrounding our patent-pending technology and the forthcoming revenue-generating innovation lab. Alicia Fantozzi, Dr. Reid Jilek, David Flores, and Dr. Hyder Khoja each possess a distinctive skill set that will play a pivotal role in steering our company's growth trajectory. Their combined expertise will propel us forward and better address the investor interest and potential collaborations as we navigate the exciting opportunities ahead."
About Mushrooms Inc. (MSRM)
Mushrooms Inc. is a publicly traded company on the OTC Markets with the stock symbol MSRM.
The vision for Mushrooms, Inc. is to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon-neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation, and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we foster will result in scientifically proven products that advance the health of body, mind, and environment.
About Dr. Reid Jilek
Dr. Jilek has advanced degrees in both the medical, life science and engineering disciplines. He was both a Presidential Fellow and a White House Fellow Candidate. He has published over 40 papers in national and international peer--reviewed scientific journals.
After completing his National Library of Medicine Post-Doctoral developing computer and mathematical models for Malaria, he decided to utilize his medical and scientific background in a business development capacity by acting as a VP of Business Development for private and public companies and a research institute.
Dr. Jilek has developed in excess of 8,000 professional contacts worldwide in the healthcare industry and investment world, to include: therapeutics, diagnostics, vaccines, gene therapy, medical devices, preclinical and clinical contract research organizations, nutraceuticals, generics, telemedicine, botanical, and biotech products, as well as the venture capital and investment banking industries.
He was a founding member of Frederick Research Center and of Asia Pacific Alliance Company. He has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies since 1990, in the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Moscow, Israel and Germany. He has also served as the CEO of four companies.
About Alicia Fantozzi
Alicia M. Fantozzi brings over 25 years of extensive expertise in project management and corporate finance to the Mushrooms Inc. Business Development Team. As Principal at ReGen, she has pioneered a seed-stage idea lab focused on applied biophysics, igniting innovation in regenerative technologies within water and agriculture sectors. With a trail of accomplishments, Alicia held the position of Chief Financial Officer at Resonant Technologies Group, propelling companies specializing in physics-based technologies for health diagnostics, immunotherapy, frequency-enabled agriculture, and material sciences. As Principal at Strategic Advisory, her influence extended to cross-border financial transactions, enhancing internal data intelligence, cyber security, and risk management. She has a proven track record in tax-structured finance and private equity, originating multi-jurisdictional tax-optimized financings for corporations and high-net-worth individuals. Alicia's remarkable experience continues to drive Mushrooms Inc.'s growth in the mushroom and psychedelic sectors.
About Dr. Hyder Khoja
Dr. Khoja, with over 22 years in Functional and Psychedelic Medicine, is a leading voice in Drug discovery and Developmental Science. He's developed treatments for Non-Alcoholic fatty liver disease using “cannabinoids” and “capsaicin”, and partnered on a project extracting Chaga Mushrooms for cancer treatment. Moreover, he's explored the potential of lipids and “Beta-Carotene” from Algae and a cancer drug from “Keyhole Limpet Hemocyanin (KLH).”
He founded "Transcendent Life Sci and Emblem Nutraceuticals, Inc," focusing on “Coma Resurrection Therapy” and the therapeutic benefits of psychotropic compounds.
Dr. Khoja acquired his Ph.D. from INP-ENSAT in 2003, trained at Michigan State University, and later joined faculties like Virginia-Tech. His 2011 research on "Algae to Biofuels" was lauded by the FAO-United Nations.
As the founder of "Transcendent Life Sci and Emblem Nutraceuticals, Inc," his legacy resonates at the intersection of science and transformation.
About David Flores
David Flores brings a wealth of visionary leadership to Mushrooms Inc.'s Business Development Team. Guiding Psychedelic and Cannabis Convergence, David Flores, CEO of PSYC Corporation and its subsidiary, Spotlight Media Corporation, is at the forefront of the psychedelic and cannabis landscape. Over the past decade, David's career has traversed legal, finance, and public markets. Based in the San Gabriel Valley of California, he drives a multimedia empire including Psychedelic Spotlight, Technical 420, and On The Bids.
David's journey began in legal and financial sectors, culminating in his leadership role. Since July 2020, he has steered Psychedelic Spotlight and PSYC Corporation's strategic growth. A former co-owner of a public and investor relations firm in Las Vegas, NV, David built connections with emerging companies in green energy and cannabis. His financial acumen was shaped by roles at respected law firms, including Greenberg Glusker LLP and Wood Smith Henning & Berman LLP.
Beyond his professional pursuits, David is a proud member of the LGBTQ+ community. He resides in West Linn, OR, with his partner and Yorkshire terrier, reflecting a multifaceted and visionary perspective.
Greetings from Mushrooms Inc.
We're excited to share our latest news (detailed in the press release below).
This announcement shines a spotlight on our newly formed Business Development Team — the unsung heroes propelling Mushrooms Inc forward. Their expertise is instrumental in our growth, exploring investment avenues, and forging intricate partnerships. With our revenue generating Innovation lab at the front of our aims, their financial acumen and holistic business view are crucial for multifaceted success. While this introduces a few team members, several others work diligently behind the scenes. Their contributions are equally invaluable.
I invite you to delve deeper into the About profiles of Dr. Jilek, Alicia Fantozzi, Dr. Khoja, and David Flores. Their distinct capabilities merit further exploration.
Thank you for your continued support of Mushrooms Inc.
Mushrooms, Inc. (OTC: MSRM) Announces Diverse Business Development Team Assembled to Drive Company Growth.
ESTERO, Fla., Aug. 23, 2023 Mushrooms Inc. (OTC:MSRM) - Mushrooms Inc., proudly introduces its newly-formed Business Development Team, strategically assembled to harness the momentum generated by the company's new technology and Innovation lab development. Comprising accomplished professionals with diverse backgrounds, this team is poised to catapult Mushrooms Inc. into a new era of innovation and growth.
Dr. Reid Jilek's inclusion reflects Mushrooms Inc.'s commitment to synergizing academic prowess with industry innovation. Holding advanced degrees in medical, life sciences, and engineering, Dr. Jilek has published extensively in national and international scientific journals. He was both a Presidential Fellow and a White House Fellow Candidate. Dr. Jilek has developed in excess of 10,000 professional contacts worldwide in the healthcare industry and investment world. His leadership roles in private and public companies, combined with a network spanning the healthcare industry, establish him as a bridge between academia and business growth.
Alicia M. Fantozzi brings over two decades of international corporate and structured finance experience to the team. With a focused track record of driving growth and fostering strategic alliances, her appointment resonates with Mushrooms Inc.'s vision. Having held key roles in strategic initiatives, Alicia's extensive experience uniquely equips her to lead the team's efforts in expanding market presence and revenue streams.
Her role as Principal at ReGen establishes a seed-stage idea lab for biomimicry-based regenerative technologies for water and agriculture., with a concentrated focus on arranging financing, field trials and propagation of advanced innovation initiatives and evaluating complimentary environmental technologies for international sustainability initiatives, Food, Water & Natural Resource Security. Her background, strategic acumen, and commitment to sustainable business practices resonate with Mushrooms Inc.’s mission of revolutionizing the mushroom industry.
Dr. Hyder Khoja, is a leading figure in the life sciences field with over 22 years of expertise spanning drug discovery, developmental science, and policy innovation. Holding a Ph.D. in "Molecular Biology" from INP-ENSAT and post-doctoral training at Michigan State University, his education grounds his visionary approach. Dr. Khoja is a distinguished scientist and visionary in the psychedelic sector, who brings a profound focus to the team. Notably, he is personally committed to pioneering the resurrection of coma patients using psilocybin, adding a transformative dimension to Mushrooms Inc.'s initiatives in the psychedelic space. Dr. Khoja is senior lead scientist in the Company’s patent pending Mycelium thread project showcasing the vast background that he brings in support of diverse projects.
David Flores, CEO of PSYC Corporation which owns and operates Psychedelic Spotlight, an industry-leading media authority for the psychedelic sector, brings his visionary leadership to the team. His strategic thinking and experience in the psychedelic landscape perfectly aligns with Mushrooms Inc.'s aspirations for developing multiple facets of the Mushroom sector. His marketing expertise and industry knowledge is integral to the Company as it evolves.
"This enhanced Business Development Team represents a pivotal milestone for Mushrooms Inc.," said Donald Steinberg, Board Director of Mushrooms Inc. "As we make strides in the mushroom sector, our team's collective experience and expertise provide a robust foundation for innovation and growth."
"We are delighted to introduce our exceptional Business Development Team," said Kimberly Zawi Carlson, CEO of Mushrooms Inc. "I've had the privilege of collaborating with these amazing individuals over the past months and I feel that they will collectively bring to Mushrooms Inc what is needed to step forward. I'm honored to announce a formal collaboration with these remarkable and versatile professionals. This strategic step is a direct response to the increasing interest surrounding our patent-pending technology and the forthcoming revenue-generating innovation lab. Alicia Fantozzi, Dr. Reid Jilek, David Flores, and Dr. Hyder Khoja each possess a distinctive skill set that will play a pivotal role in steering our company's growth trajectory. Their combined expertise will propel us forward and better address the investor interest and potential collaborations as we navigate the exciting opportunities ahead."
About Mushrooms Inc. (MSRM)
Mushrooms Inc. is a publicly traded company on the OTC Markets with the stock symbol MSRM.
The vision for Mushrooms, Inc. is to support the growth of the mushroom industry through collaboration, innovation and development. Creating and supporting environmentally beneficial product innovation is at the heart of Mushrooms, Inc. Our current focus is on the industrial application of Mycelium for the creation of carbon-neutral products for the building and health care industries as well as creating supplements based on the proven health benefits of mushrooms. Research and Development is the path to achieving great innovation, and the pioneers are the ones we look to for their fortitude and enduring dedication to the world of mycology. The working relationships we foster will result in scientifically proven products that advance the health of body, mind, and environment.
About Dr. Reid Jilek
Dr. Jilek has advanced degrees in both the medical, life science and engineering disciplines. He was both a Presidential Fellow and a White House Fellow Candidate. He has published over 40 papers in national and international peer--reviewed scientific journals.
After completing his National Library of Medicine Post-Doctoral developing computer and mathematical models for Malaria, he decided to utilize his medical and scientific background in a business development capacity by acting as a VP of Business Development for private and public companies and a research institute.
Dr. Jilek has developed in excess of 8,000 professional contacts worldwide in the healthcare industry and investment world, to include: therapeutics, diagnostics, vaccines, gene therapy, medical devices, preclinical and clinical contract research organizations, nutraceuticals, generics, telemedicine, botanical, and biotech products, as well as the venture capital and investment banking industries.
He was a founding member of Frederick Research Center and of Asia Pacific Alliance Company. He has served on the Board of Directors, Scientific or Medical Advisory Boards, or Advisory Boards for more than 40 private and public companies since 1990, in the US, Canada, Mexico, Japan, Taiwan, China, Portugal, Moscow, Israel and Germany. He has also served as the CEO of four companies.
About Alicia Fantozzi
Alicia M. Fantozzi brings over 25 years of extensive expertise in project management and corporate finance to the Mushrooms Inc. Business Development Team. As Principal at ReGen, she has pioneered a seed-stage idea lab focused on applied biophysics, igniting innovation in regenerative technologies within water and agriculture sectors. With a trail of accomplishments, Alicia held the position of Chief Financial Officer at Resonant Technologies Group, propelling companies specializing in physics-based technologies for health diagnostics, immunotherapy, frequency-enabled agriculture, and material sciences. As Principal at Strategic Advisory, her influence extended to cross-border financial transactions, enhancing internal data intelligence, cyber security, and risk management. She has a proven track record in tax-structured finance and private equity, originating multi-jurisdictional tax-optimized financings for corporations and high-net-worth individuals. Alicia's remarkable experience continues to drive Mushrooms Inc.'s growth in the mushroom and psychedelic sectors.
About Dr. Hyder Khoja
Dr. Khoja, with over 22 years in Functional and Psychedelic Medicine, is a leading voice in Drug discovery and Developmental Science. He's developed treatments for Non-Alcoholic fatty liver disease using “cannabinoids” and “capsaicin”, and partnered on a project extracting Chaga Mushrooms for cancer treatment. Moreover, he's explored the potential of lipids and “Beta-Carotene” from Algae and a cancer drug from “Keyhole Limpet Hemocyanin (KLH).”
He founded "Transcendent Life Sci and Emblem Nutraceuticals, Inc," focusing on “Coma Resurrection Therapy” and the therapeutic benefits of psychotropic compounds.
Dr. Khoja acquired his Ph.D. from INP-ENSAT in 2003, trained at Michigan State University, and later joined faculties like Virginia-Tech. His 2011 research on "Algae to Biofuels" was lauded by the FAO-United Nations.
As the founder of "Transcendent Life Sci and Emblem Nutraceuticals, Inc," his legacy resonates at the intersection of science and transformation.
About David Flores
David Flores brings a wealth of visionary leadership to Mushrooms Inc.'s Business Development Team. Guiding Psychedelic and Cannabis Convergence, David Flores, CEO of PSYC Corporation and its subsidiary, Spotlight Media Corporation, is at the forefront of the psychedelic and cannabis landscape. Over the past decade, David's career has traversed legal, finance, and public markets. Based in the San Gabriel Valley of California, he drives a multimedia empire including Psychedelic Spotlight, Technical 420, and On The Bids.
David's journey began in legal and financial sectors, culminating in his leadership role. Since July 2020, he has steered Psychedelic Spotlight and PSYC Corporation's strategic growth. A former co-owner of a public and investor relations firm in Las Vegas, NV, David built connections with emerging companies in green energy and cannabis. His financial acumen was shaped by roles at respected law firms, including Greenberg Glusker LLP and Wood Smith Henning & Berman LLP.
Beyond his professional pursuits, David is a proud member of the LGBTQ+ community. He resides in West Linn, OR, with his partner and Yorkshire terrier, reflecting a multifaceted and visionary perspective.
Prior Press Releases
Poised for Textile Innovation and Global Impact as Full Patent Filing for Mycelium Thread Nears Completion
CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast
Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market Leaders
Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM”
acquisitions late august in the podcast
I can't recall -- when the CEO in the podcast mentioned updates coming in august was that to the just released patent news...or already updates to acquisitions? Either way lets see what the next three months bring...so far she has followed the business layout like a clockwork
Nice close lets get those acquisitions she spoke about last month on the podcast
6M tradable shares only! 2 year pps high of $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/22/2023
Restricted 32,527,735 08/22/2023
Unrestricted 5,958,025 08/22/2023
absolutely...golden cross ~0.048 !!!!
Listen to the recent interview featuring MSRM CEO Kimberly Carlson (where she addresses preserving the share structure and not taking convertible debt) https://psychedelicspotlight.com/using-mycelium-for-a-sustainable-future-feat-kimberly-carlson/
Ya this one will be good if the can keep the share structure.
Anyone following this one??? the patent news is the value added option here, very undervalued imho
Dr. Khoja expressed, "We have brought together many years of innovative research in a short time to bring forth a more groundbreaking textile than Mushrooms Inc. had expected when filing the provisional patent for mycelium thread.
The company is now in the final stages of filing a full patent application for its groundbreaking mycelium thread technology.....At the helm of this groundbreaking project is Dr. Hyder Ali Khoja, the senior lead scientist for the Myco Thread project, whose expertise and vision have been instrumental in unlocking the true potential of mycelium thread. Together with his exceptional team led by Maqsad Suriev, lead project chemist, they have achieved remarkable advancements....
Dr. Khoja expressed, "We have brought together many years of innovative research in a short time to bring forth a more groundbreaking textile than Mushrooms Inc. had expected when filing the provisional patent for mycelium thread.
08/08/2023: Mushrooms, Inc. (OTC: MSRM) is Poised for Textile Innovation and Global Impact as Full Patent Filing for Mycelium Thread Nears Completion
ESTERO, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- via IBN -- Mushrooms Inc. (OTC:MSRM), a trailblazer in sustainable textile innovation, is thrilled to announce a continuation of its mission to revolutionize the textile industry. The company is now in the final stages of filing a full patent application for its groundbreaking mycelium thread technology, representing a significant stride towards a more sustainable and ecologically conscious future while advancing science and technology.
The unique characteristics of the mycelium thread position it as a transformative force across various sectors, spanning medical, military, aerospace, lifestyle, and environmental applications. Drawing from the natural properties of mycelium, coupled with ingenious elements, the textile exhibits inherent antimicrobial qualities and the ability for microbial detection.
"This project showcases that holding to high environmental standards does not mean a sacrifice of technological advancements; in fact, it exemplifies the opposite. By working in partnership with nature, it gives back tenfold," stated CEO Kimberly Carlson of Mushrooms Inc.
While celebrating this pivotal moment, Mushrooms Inc. recognizes the importance of safeguarding its proprietary technology. In this phase, specific details and the intricate science behind the mycelium thread will remain confidential to protect its intellectual property and maintain a competitive edge.
At the helm of this groundbreaking project is Dr. Hyder Ali Khoja, the senior lead scientist for the Myco Thread project, whose expertise and vision have been instrumental in unlocking the true potential of mycelium thread. Together with his exceptional team led by Maqsad Suriev, lead project chemist, they have achieved remarkable advancements that hold the power to revolutionize how textiles are produced and utilized, with profound environmental and functional advantages.
"Dr. Hyder Khoja's role as our senior lead scientist on this project has been indispensable in driving this innovation forward. His diverse accomplishments in science and collaborative dedication have combined to pave the way for the mycelium thread's transformative impact," said Carlson.
Dr. Khoja expressed, "We have brought together many years of innovative research in a short time to bring forth a more groundbreaking textile than Mushrooms Inc. had expected when filing the provisional patent for mycelium thread. We have taken this textile innovation to a new level with microbial detection which we believe, coupled with the natural properties and therapeutic potential of mycelium, will revolutionize the medical sector on a global scale. Being customizable in its attributes allows for endless branches of innovation into vast sectors."
As the patent application undergoes regulatory review, Mushrooms Inc. actively explores strategic partnerships and investment opportunities that align with its mission. The company invites stakeholders, industry partners, and investors who share the vision of a greener, cleaner future to unite in bringing this transformative technology to market.
As Mushrooms Inc. nears the final stages of full patent filing for its innovative mycelium thread technology, the company is strategically planning for its commercialization and global impact. The monetization strategy includes exploring licensing opportunities with industry partners to expand the adoption of this revolutionary textile across various sectors.
Additionally, Mushrooms Inc. is committed to internal development, aiming to bring finished mycelium-based products to market under its brand. The company is also inviting first-use investors who share its vision of sustainable innovation to participate in early-stage funding, ensuring the mycelium thread's rapid integration into the global market. By combining licensing, internal development, and strategic investment, Mushrooms Inc. aims to usher in a new era of eco-friendly textiles and environmentally conscious products for a better, greener world.
Looking forward, Mushrooms Inc. envisions a world where textiles are not just commodities but customizable catalysts for a healthier planet. The company firmly believes that a sustainable future can be achieved through collaborative efforts with nature and a steadfast commitment to innovation.
Timely industry, small float. Not going to take much to get this one rocking and rolling!!!!
6M tradable shares only! 53week high pps $0.014! 2 year high $2.9
Unrestricted: Unchanged
Restricted: Unchanged
OS: Unchanged
Outstanding Shares 38,485,760 08/01/2023
Restricted 32,527,735 08/01/2023
Unrestricted 5,958,025 08/01/2023
I hold not too many (280K) but, likewise, will be patient.
Yes. My college age daughter turned $500 into ~$4000 in the last 2 years with occasional logging into her account and, likewise, some OTC ticker flips,,,even she has bought some MSRM 40K shares here to "make her rich" by 2025 :)
And I think thats a nice approach.
August is almost upon us which will be the beginning for msrm do yourself a favor and listen to the podcast, we have an awesome ceo who isn’t interested in convertibles notes, gonna build with acquisitions in a new up and coming field we should be volume next week if anyone has a brain
its going up and I don't have enough shares
Thanks for the PM.
Right, My point was I almost overlooked this one.
IHUB CHART , makes it look like it already ran.
Looking at it on a decent platform, the Bollinger bands are tight and ready for an explosion.
Looks like it has plenty of room to run.
GLta
Things like this can be 1 cent this week, 10 cents next week, back to 2 cents next month, $1 next year (or august this year = see CEO remarks in podcast)
depends at how you look at the entry...2 yrs ago this shot to $pps and exactly 1 year ago to 40cent pps.
Everything's a gamble on the OTC but whether buying at 1.5 cent or 3 cent doesn't matter long term IMO. My ave is ~3.4 cents
I was hoping to get more loaded before this took off.
I checked this out a few times using Ihub charts. That was a mistake. I finally looked at it on a decent platform.
Another lesson learned.
yep and she should have no problem getting investors
listened myself: CEO is informed, quick thinking, eloquent, determined, business model sound, etc. etc.; esp 12 min in: tiny preserved SS, no convertible notes coming, etc.
yes just did loved it
Great interview! Acquisitions coming August timeframe, she doesnt want dilution, around 1M mkt cap just silly were in for a nice ride here
CEO is very responsive (emails) but listening to the podcast will reveal way more about her ambitions, goals, approaches. Yes, this industry and sector should offer endless scientific and product opportunities
With a name like mushrooms Inc we should draw a good acqusition at some pt
MSRM: Update & Acquisitions...Unrestricted shares preserved at 6M
Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast.
Estero, FL, July 19, 2023 – Mushrooms Inc. (OTC: MSRM) (the “Company” or “MSRM) is pleased to announce that its CEO, Kimberly Carlson, recently appeared on the esteemed Psychedelic Spotlight Podcast to discuss the exciting potential of the industrial mushroom industry. As the first company trading on the US stock market focused on the industrial side of mushrooms, Mushrooms Inc. is leading the way in revolutionizing this emerging sector.
To watch or listen to the complete interview featuring Kimberly Carlson on Psychedelic Spotlight, please visit the following link: https://psychedelicspotlight.com/using-mycelium-for-a-sustainable-future-feat-kimberly-carlson/
During the podcast episode hosted by David Flores (CEO of Psychedelic Spotlight), Kimberly Carlson shared insights into the vision and mission of Mushrooms Inc. The Company is dedicated to supporting the growth of the mushroom industry through collaboration, innovation, and development. At the heart of Mushrooms Inc. lies a commitment to creating and supporting environmentally beneficial product innovation.
With a specific focus on the industrial application of mycelium, Mushrooms Inc. aims to develop carbon-neutral products for the building, textile, and healthcare industries. By harnessing the power of mycology, Mushrooms Inc. seeks to advance the creation of scientifically proven products that promote the health of the body, mind, and environment which includes remediation of toxic substances using mycelium also known as Myco-remediation.
Along with providing Mr. Flores with an overview of Mushrooms Inc., Ms. Carlson also shared insight into her own personal passion for working within the mushroom sector and why she believes mycelium holds the potential to promote a healthier and more sustainable environment for all of society.
"The potential of the industrial mushroom sector is immense, and Mushrooms Inc. is at the forefront of driving innovation in this field," said Kimberly Carlson, CEO of Mushrooms Inc. "Through our research and development efforts, we are committed to delivering sustainable solutions that benefit not only our customers but also the planet.
I am grateful for the opportunity to have had Mushrooms Inc. featured on the Psychedelic Spotlight Podcast, and more specifically, for the opportunity to provide their audience, as well as many others following the public markets, with an initial introduction into some the exiting things we have planned for MSRM.
In the weeks and months ahead, I look forward to being able to share some of the progress we anticipate making as we strive to truly position MSRM as an industrial mushroom leader.”
Mushrooms Inc. recognizes that true innovation comes from collaboration and learning from pioneers in the field. By fostering working relationships and engaging with experts in mycology, the Company is paving the way for groundbreaking advancements in the industry.
Mushrooms Inc. (OTC: MSRM) Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market LeadersPress Release | 02/23/2023
ESTERO, FL / ACCESSWIRE / February 23, 2023 / Mushrooms, Inc. (OTC PINK:MSRM) (the "Company") has been quietly making progress within this exciting multi-billion-dollar market opportunity currently being opened by new mycelium-based materials science and biotechnology.
Mushrooms Inc. is developing profitable pathways to sustain the research and development branch which is necessary to achieve viable industrial innovation in this new field.
MSRM is targeting grants specific to their goals, working with pioneers, scientists, and universities, on a global scale to develop scientifically proven products that advance health of body, mind, and environment. They have multiple proposals that they are currently reviewing for their costs to bring to market, timelines, scalability, as well as their positive financial, environmental and health impact. These proposals include a patentable process for the development of mycelium-based building supplies, a patentable process for mushroom related cosmetic and anti-aging skin products, a superfood product not currently seen in the marketplace as well as several remediation projects with new product innovation as an end result. These proposals are being assessed while keeping the progress on an off-shore lab and scientists for an evolved patentable mycelium thread.
GROWTH STRATEGY
In order to offset research costs and time on the industrial development side we are establishing pillars of development outside of the industrial mushroom market through acquisitions and joint ventures. The business model is based on the amazing qualities of mycelium and its networking capabilities as well as its ability to benefit from the network its developing.
CEO Kimberly Carlson shared, "I have been fortunate to connect with amazing pioneers and innovators in differing areas of the Mushroom Market in the US and abroad. Three realities have been consistent with the people behind the businesses and their processes. One is that this business model can bring like-minded companies together in order to benefit and fruit from a shared network under the public umbrella. Secondly, there are natural and substantial cross-points between these companies to mutually benefit from each other while growing as a whole. And the third is that there is a desire for many of these businesses to unite their expertise to others and share from a unified gain. By combining the power of shared ideals and resources through joint ventures, we can move as larger more developed companies do, but without limiting quality and compassion for social and environmental governance."
With a focus on profitability and mutually beneficial cross points, MSRM is assessing partnerships with complimentary businesses which would strategically advance the Company's reach into related markets through joint ventures and M&A activity.
Establishing pillars of development outside of the industrial mushroom market allows for a broad scope of proven profitability and cross-sharing of resources.
We seek to enter partnerships in the Cultivation Market, which includes substrate, spawn production, and fruiting. Cultivation gives life to all market pillars to some degree. It feeds directly into the Mushroom Nutraceutical and Medicinal Psylocibin Market with the addition of extraction, quality testing, product development, and processing. The Medicinal Mushroom Market requires legalization and branches into wellness retreats, treatment certifications and clinics.
MSRM is also evaluating several companies involved in the Myco-Remediation Market which uses fungi to clean oil spills, heavy metals, plastics and other pollutants from soil, water, and the atmosphere. All of these markets relate to the industrial and health innovation that the Company is pursuing in differing aspects and creates a connecting point for acceleration, mutual benefit and market share.
It is the belief of MSRM that connecting these pillars of the mushroom market through joint ventures and acquisitions, while focusing their innovation efforts on the industrial side of the market, will garner cross benefits financially and accelerate timelines during the major research and development phases.
We are simultaneously creating a vertically integrated business model for the businesses involved by aligning strengths between the companies under the umbrella of MSRM.
From an investor perspective, we are creating an avenue for investors to support a larger portion of the mushroom market, establishing a broader financial base of support for and from the networked companies while allowing for a more elastic ability to pivot, expand and connect to new industry pathways as they surface.
Market Opportunity
Mushrooms, Inc. operates in the North American segment of the functional mushroom market in the mycelium material and mushroom supplement product types. According to various industrial research firms, the global functional mushroom market is projected to show a compounded annual growth rate of over 9% for the next five years (Industry Arc and Vantage Market Research). The North American edible mushroom market was worth 11.99 billion in 2023 and is growing at a compounded annual growth rate of 9.48%, forecast to reach 20.91 billion by 2028 (Market Data Forecast). The North American functional mushroom market held 33.8% of the global market in 2020 and is growing at a compounded annual growth rate of 7% (Industry Arc).
Overview
Mushrooms, Inc. is a developing-stage emerging consumer products platform focused on the manufacturing and marketing of highly differentiated mushroom-based materials and functional supplements. The core growth pillars of the Mushrooms, Inc. platform are currently based on developing functional mushroom technologies. As a result of growing consumer demand for innovative, sustainable, and carbon-neutral products, Mushrooms, Inc. plans to grow revenues by penetrating the multi-billion-dollar market opportunity currently being opened by new mycelium-based materials science and biotechnology, as well as expanding our platform to include the creation of supplements based on the proven health benefits of mushrooms.
Mushrooms, Inc. seeks to drive the growth of the bourgeoning functional mushroom industry through product innovation and development. Our current core business activity is environmentally beneficial product innovation utilizing self-growing, fibrous, and natural composite materials with controlled physical properties that can be produced in large quantities. Our product technologies focus on mycelium, the main component of fungi. This emerging biotechnology is used in the creation of carbon neutral products for the building, textile, packaging, and health care industries, as well as in the creation of supplements based on the proven health benefits of mushrooms.
Currently, our research focuses primarily on the significant thermal stability of mycelium materials, a result of mycelium's unique degradation qualities that expand the potential fields of application for mushroom-based products. Mushrooms, Inc.'s long-term goal is to build a strong scalable and widely recognized brand that authentically focuses on sustainable mushroom ingredients and novel functionality stemming from innovative biotech and materials science.
For more information, email info@mushroomsinc.com or visit www.mushroomsinc.com
07/19/2023 Mushrooms Inc. CEO, Kimberly Carlson, Discusses Exciting Potential of Industrial Mushroom Industry on Psychedelic Spotlight Podcast Press Release
02/23/2023 Mushrooms Inc. (OTC: MSRM) Announces Plan for Acquisitions and Vertically Integrated Business Development by Partnering with diversified Mushroom Market LeadersPress Release
04/20/2023 Quarterly Report for the period ended March 31, 2023
03/06/2023 Attorney Letter with Respect to Current Information - Shell Status Opinion MSRM
03/06/2023 Attorney Letter with Respect to Current Information - MSRM - Current Information Letter
03/06/2023 Annual Report - MSRM 2022 Annual Report
11/29/2022 Mushrooms, Inc. Announces Name and Ticker Symbol Change on OTC Markets to “MSRM” Press Release
https://www.otcmarkets.com/stock/MSRM/disclosure
08/23/2022 Marijuana Strategic Ventures, Inc. (OTC: MSVI) Now Mushrooms Inc., Announces Filing of Provisional Patent for Novel Mycelium Thread Press Release
Outstanding Shares 38,485,760 07/18/2023
Restricted 32,527,735 07/18/2023
Unrestricted 5,958,025 07/18/2023
Authorized Shares 400,000,000 07/18/2023
update by CEO:
see twitter https://twitter.com/MushroomsInc
MSRM This is totally under the Radar and is REAL. Check the SS , they did file a Patent that is coming up , they do have the product and their Mgt Team actually knows what they are doing.
https://otcmarkets.com/stock/MSRM/security
https://mushroomsinc.com/team-3
https://twitter.com/MushroomsInc
come on Kim give us something good with a name like and such low float
Followers
|
66
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
3225
|
Created
|
11/23/07
|
Type
|
Free
|
Moderators i_like_bb_stock 2times2 |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |